Osteonovus
Private Company
Total funding raised: $3.2M
Overview
OsteoNovus is a commercial-stage orthopedic company with an FDA-cleared product, NovoGro Putty, for bone regeneration. Its core innovation is a bioactive synthetic graft material that mimics natural bone mineral, encouraging rapid bone ingrowth and remodeling, as evidenced by robust preclinical data showing new bone formation within six weeks. The company is advancing its pipeline with an injectable formulation of NovoGro, aiming to expand its addressable market into minimally invasive procedures. Operating from the orthopedic hub of Memphis, OsteoNovus is positioned to capture share in the large and growing bone graft substitute market.
Technology Platform
Bioactive synthetic bone graft platform that forms biomimetic apatite crystals in vivo, promoting osteoconduction and remodeling into natural bone. Can be formulated into cohesive putty and injectable formats with excellent handling properties.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
OsteoNovus competes in the synthetic bone graft segment against major players like Medtronic (Infuse, Mastergraft), Stryker (Vitoss), Zimmer Biomet (CopiOs), and Baxter (Integra Mozaik). It differentiates through its bioactive apatite-forming technology and specific handling claims (won't wash out, sticks to wet bone). Smaller innovators also compete in the moldable/putty segment, making differentiation and clinical proof critical.